Target validation

Current Opinion in Pharmacology

Volumn 3, Issue 5, 2003, Pages 571-577

  Williams, Michael ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIASTHMATIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIMIGRAINE AGENT; ANTISENSE OLIGONUCLEOTIDE; CIMETIDINE; CLOZAPINE; COMPLEMENTARY DNA; CYCLOOXYGENASE 2 INHIBITOR; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; HALOPERIDOL; HISTAMINE H2 RECEPTOR ANTAGONIST; HISTAMINE H4 RECEPTOR; LOSARTAN; MESSENGER RNA; MORPHINE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROLEPTIC AGENT; NOCICEPTIN; NOCICEPTIN RECEPTOR; OLANZAPINE; PURINE P2X RECEPTOR; RANITIDINE; SALMETEROL; SEROTONIN 6 RECEPTOR; SUMATRIPTAN; UNINDEXED DRUG;

DNA MICROARRAY; DRUG ADSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOXICITY; GENE IDENTIFICATION; GENE SEQUENCE; GENOTYPE; HUMAN GENOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PROTEOMICS; RAT; REVIEW; SEQUENCE HOMOLOGY; VALIDATION PROCESS;

ANIMALS; DRUG DESIGN; GENOME, HUMAN; GENOMICS; HUMANS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOMICS; RECEPTORS, G-PROTEIN-COUPLED; TECHNOLOGY, PHARMACEUTICAL;

EID: 0141646495     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2003.06.001     Document Type: Review

References (58)

1. Pollack A: Despite billions for discoveries, pipeline of drugs is far from full. New York Times April 19th 2002.
2. Harris G: A drug giant thinks it can grow still bigger. New York Times Business Day June 19th 2003:C1-C2.
3. DiMasi J.S. Hansen R.W. Grabowski H.G. The price of innovation: new estimates of drug development costs J. Health Econom. 22 2003 151-185
4. Longman R: Pharma future: is the glass half-empty or half-full? In Vivo: The Business and Medicine Report, April 2002:15-28.
5. Scrip: 7,000 new products in R & D, the highest ever. Scrip May 16th 2003:25.
6. Horrobin D.F. Realism in drug discovery - could Cassandra be right? Nature Biotech. 19 2001 1099-1100
7. Venter J.C. Adams M.D. Myers E.W. Li P.W. Mural R.J. Sutton G.G. Smith H.O. Yandell M. Evans C.A. Holt R.A. et al. The sequence of the human genome Science 291 2001 1304-1351
8. Lander E.S. Linton L.M. Birren B. Nusbaum C. Zody M.C. Baldwin J. Devon K. Dewar K. Doyle M. FitzHugh W. et al. Initial sequencing and analysis of the human genome Nature 409 2001 860-921
9. Collins F.S. Green E.D. Guttmacher A.E. Guyer M.S. US National Human Genome Research Institute: a vision for the future of genomics research Nature 422 2003 835-847
10. Frantz S. In vivo we trust Nature Rev. Drug. Discov. 2 2003 501
11. Henry C.M. Systems biology Chem. Eng. News 81 2003 45-55
12. Bailey S.N. Wu R.Z. Sabatini D.M. Applications of transfected cell microarrays in high-throughput drug discovery Drug. Discov. Today 7 2003 S113-S118
13. Bunney W.E. Bunney B.G. Vawter M.P. Tomita H. Li J. Evans S.J. Choudary P.V. Myers R.M. Jones E.G. Watson S.J. Akil H. Microarray technology: a review of new strategies to discover candidate vulnerability genes in psychiatric disorders Am. J. Psychiatry 160 2003 657-666
14. Butte A. The use and analysis of microarray data Nat. Rev. Drug. Discov. 1 2002 951-960
15. Firestein G.S. Pisetsky D.S. DNA microarrays: boundless technology or bound by technology? Guidelines for studies using microarray technology Arthritis Rheum. 46 2002 859-861
16. Wise A. Gearing A.K. Rees S. Target validation of G-protein coupled receptors Trends Pharmacol. Sci. 7 2002 235-246
17. Crooke ST: Oligonucleotide therapeutics. In Burger's Medicinal Chemistry and Drug Discovery, edn 6, vol 2. Edited by Abraham DJ. Hoboken, NJ: Wiley; 2003:115-166.
18. Stipp D: Biotech's billion dollar breakthrough. Fortune May 26th 2003:96-104.
19. Hannon G.J. RNA interference Nature 418 2002 244-251
20. Krichevsky A.M. Kosik K.S. RNAi functions in cultured mammalian neurons Proc. Natl. Acad. Sci. U S A 99 2002 11926-11929
21. Mendelsohn A.R. Brent R. Protein interaction methods: towards an endgame Science 284 1999 1948-1950
22. Mitchell P. In the pursuit of industrial proteomics Nat. Biotechnol. 21 2003 233-237
23. Hanash S. Disease proteomics Nature 422 2003 226-232
24. Weir M.P. Overington J.P. Schwarz M. Expanding and exploring cellular pathways for novel drug targets Annu. Rep. Med. Chem. 37 2002 187-196
25. Patterson S.D. Data analysis - the Achilles heel of proteomics Nature Biotechnol. 21 2003 221-222
26. Taylor C.F. Paton N.W. Garwood K.L. Kirby P.D. Stead D.A. Yin Z. Deutsch E.W. Selway L. Walker J. Riba-Garcia I. et al. A systematic approach to modeling, capturing, and disseminating proteomics experimental data Nat. Biotechnol. 21 2003 247-254
27. Anderson N.L. Anderson N.G. The human plasma proteome Mol. Cell. Proteomics 1 2002 845-867
28. Lenz G.R. Nash H.M. Jinfal S. Chemical ligands, genomics and drug discovery Drug Discov. Today 5 2000 145-156
29. Bockaert J. Pin J.P. Molecular tinkering of G-protein-coupled receptors: an evolutionary success EMBO J. 18 1999 1723-1729
30. Chalmers D.T. Behan D.P. The use of constitutively active GPCRs in drug discovery and functional genomics Nat. Rev. Drug Discov. 1 2002 599-608
31. Drews J. Drug discovery: a historical perspective Science 287 2000 1960-1964
32. Civelli O. Nothacker H.-P. Saito Y. Wang Z. Lin S.H. Reinscheid R.K. Novel neurotransmitters as natural ligands of orphan G-protein-coupled receptors Trends Neurosci. 24 2001 230-237
33. Howard A.D. McAllister G. Feighner S.D. Liu Q. Nargund R.P. Van der Ploeg L.H. Patchett A.A. Orphan G-protein-coupled receptors and natural ligand discovery Trends Pharmacol. Sci. 22 2001 132-140
34. Jenck F. Wichmann J. Dautzenberg F.M. Moreau J.L. Ouagazzal A.M. Martin J.R. Lundstrom K. Cesura A.M. Poli S.M. Roever S. et al. A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat Proc. Natl. Acad. Sci. U S A 97 2000 4938-4943
35. Mirnics K. Middleton F.A. Lewis D.A. Levitt P. Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse Trends Neurosci. 24 2001 479-486
36. Hemby S.E. Ginsberg S.D. Brunk B. Arnold S.E. Trojanowski J.Q. Eberwine J.H. Gene expression profile for schizophrenia: discrete neuron transcription patterns in the entorhinal cortex Arch. Gen. Psychiatry 59 2002 631-640
37. Mandel S. Weinreb O. Youdim M.B.H. Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs Trends Pharmacol. Sci. 24 2003 184-191
38. Legrain P. Wojcik J. Gauthier J.-M. Protein-protein interactive maps: leads towards cellular function Trends Genet. 17 2001 346-352
39. Zambrowicz B.P. Sands A.T. Knockouts model the 100 best-selling drugs - will they model the next 100? Nat. Rev. Drug Discov. 2 2003 38-51
40. Abraham W.C. Logan B. Thompson V.L. Williams J.M. Tate W.P. Sequence-independent effects of phosphothiolated oligonucleotides on synaptic transmission and excitability in the hippocampus in vivo Neuropharmacology 36 1997 345-352
41. 3 antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states Pain 99 2002 11-19
42. 2/3 receptors reduces chronic inflammatory and neuropathic pain in rat Proc. Natl. Acad. Sci. U S A 99 2002 17179-17184
43. Stockwell B.R. Chemical genetics: ligand-based discovery of gene function Nat. Rev. Genet. 1 2000 116-125
44. Schrieber S.L. Targeted- oriented and diversity-oriented organic synthesis in drug discovery Science 287 2000 1964-1969
45. Makara G.M. Measuring molecular similarity and diversity: total pharmacophore diversity J. Med. Chem. 44 2001 3563-3571
46. Ma Q.-P. Hill R.G. Neurokinin antagonists as potential agents for use in pain management Curr. Opin. CPNS Invest. Drugs 1 1999 65-71
47. Dionne R.A. Clinical analgesic trials of NK1 antagonists Curr. Opin. CPNS Invest. Drugs 1 1999 82-85
48. 1 (substance P) receptor antagonists - why are they not analgesic in humans? Trends Pharmacol. Sci. 21 2000 244-246
49. Cloninger C.R. The discovery of susceptibility genes for mental disorders Proc. Natl. Acad. Sci. U S A 99 2002 13365-13367
50. Sawa A. Snyder S.H. Schizophrenia: diverse approaches to a complex disease Science 296 2002 692-695
51. Williams M. Genome-based drug discovery: prioritizing disease susceptibility/disease-associated genes as novel drug targets for schizophrenia Curr. Opin. Investig. Drugs 4 2003 31-36
52. Brzustowicz L.M. Hodgkinson K.A. Chow E.W.C. Honer W.G. Bassett A.S. Location of a major susceptibility locus for familial schizophrenia on Chromosome 1q21-22 Science 288 2000 678-682
53. Levinson D.F. Holmans P.A. Laurent C. Riley B. Pulver A.E. Gejman P.V. Schwab S.G. Williams N.M. Owen M.J. Wildenauer D.B. et al. No major schizophrenia locus detected on chromosome 1q in a large multicenter sample Science 296 2002 739-741
54. Straub R.E. MacLean C.J. O'Neill F.A. Burke J. Murphy B. Duke F. Shinkwin R. Webb B.T. Zhang J. Walsh D. et al. A potential vulnerability locus for schizophrenia on chromosome 6p24-22: evidence for genetic heterogeneity Nat. Genet. 11 1995 287-293
55. Kendler KS: Molecular genetics of schizophrenia. In Neurobiology of Mental Illness. Edited by Charney DS, Bunney BS, Nestler E. New York: Oxford University Press; 2000:203-213.
56. Williams R.S.B. Cheng L. Mudge A.W. Harwood A.J. A common mechanism of action for three mood stabilizing drugs Nature 417 2002 292-295
57. Lazo J.S. Ducruet A.P. Koldamova R.P. Sleuthful pharmacology Mol. Pharmacol. 64 2003 199-201
58. Efferth T. Sauerbrey A. Olbrich A. Gebhart E. Rauch P. Weber H.O. Hengstler J.G. Halatsch M.E. Volm M. Tew K.D. et al. Molecular modes of action of artesunate in tumor cell lines Mol. Pharmacol. 64 2003 382-394